In a prespecified secondary analysis of the phase 3 SELECT trial, once-weekly semaglutide 2.4 mg reduced high-sensitivity C-reactive protein by 37.8% versus placebo at 104 weeks among adults with...
In this video, Brittany Albright, MD, discusses why primary care clinicians are often the first line of defense in recognizing and treating anxiety disorders. She reviews practical strategies for screening,...
The FDA approved the first-in-class targeted therapy based on a clinical trial evaluating overall survival among adults with previously treated metastatic pancreatic adenocarcinoma.
In the double-blind EPCAT III RCT, aspirin alone was noninferior to 5 days of rivaroxaban followed by aspirin for preventing symptomatic VTE after total hip or knee arthroplasty, with no clinically relevant...
A systematic review and pooled meta-analysis of 17 RCTs involving 5,500 adolescents and adults found little evidence that very low nicotine content cigarettes increased cigarette consumption or carbon...
The FDA approval introduces a nonprescription fixed-dose combination of 2 widely used analgesics for temporary relief of common minor aches and pains in adults and children aged 12 years or older.
Improving TDF-FTC uptake among US young men who have sex with men on HIV PrEP could yield substantial 10-year value, while a hypothetical study eliminating adverse event uncertainty would not change the...
In two phase 3, double-blind, placebo-controlled trials of adults with noncirrhotic chronic hepatitis B virus infection receiving stable nucleoside or nucleotide analog therapy, 24 weeks of bepirovirsen...
